Short Term Trading Week Starting: 19 November 2018, page-57

PAR

Paradigm Biopharma - under the radar but pretty big announcement today. Acquired a license to another indication worth $Bs per annum once commercialised. Acquisition includes successful Phase 2a data. Attractive terms (no dilution, small upfront fully funded by recent placement, single digit royalties). Synergies with their main target of OsteoArthritis so complimentary body of data, helping with submissions. Pretty much just doubled their prospective market, added another shot on goal, and a potential short path to market being an orphan indication. "High probability of developing a commercial product".